Shout out to Oncology!

Quote

Anonymous

Guest
Great job you seasoned professionals!! Looks like you "leaders of the space" have racked up an impressive average of 2 patients per territory since launch!

Or in other words your entire division produces about one day of HCV sales in a year. Amazing contribution! I believe that covers the sushi budget at the Foster City cafeteria this year!

Thanks again for your unmatched oncology relationships and hard earned expertise.
Without you all we would have never been able to seize the pole position in this challenging therapeutic space quite like we have.

Good luck at your next venture in the industry! If I know Uncle Gilead this free ride will be coming to an end soon!
 


















Anonymous said:
Great job you seasoned professionals!! Looks like you "leaders of the space" have racked up an impressive average of 2 patients per territory since launch!

Or in other words your entire division produces about one day of HCV sales in a year. Amazing contribution! I believe that covers the sushi budget at the Foster City cafeteria this year!

Thanks again for your unmatched oncology relationships and hard earned expertise.
Without you all we would have never been able to seize the pole position in this challenging therapeutic space quite like we have.

Good luck at your next venture in the industry! If I know Uncle Gilead this free ride will be coming to an end soon!
Click to expand...
Is it true that someone won rep of the year with 5 scripts?
 






Yep. $25 million dollars that avg 2 patients per territory. This drug is the biggest dog with fleas ever. Why did I leave device for this nightmare and no bonus money. Stock is partial vested so get me out of here!
 






Exciting things are happening for oncology sales professionals at EMD Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany. We are significantly expanding our oncology and immuno-oncology footprint thanks in part, to the success of our R&D pipeline, and the recent partnership with Pfizer, to co-promote and co-develop immuno-oncology assets within each company.

Preparations are underway for the launch of evofosfamide, a hypoxia-targeted drug for the treatment of pancreatic adenocarcinoma. Avelumab, our fully human anti-PD-L1 therapeutic antibody, is under late stage development against several tumor types. Our development efforts will also explore the efficacy of combination therapies with existing and novel therapies.

EMD Serono is currently recruiting Key Account Managers for our Oncology division.
 












Anonymous said:
Great job you seasoned professionals!! Looks like you "leaders of the space" have racked up an impressive average of 2 patients per territory since launch!

Or in other words your entire division produces about one day of HCV sales in a year. Amazing contribution! I believe that covers the sushi budget at the Foster City cafeteria this year!

Thanks again for your unmatched oncology relationships and hard earned expertise.
Without you all we would have never been able to seize the pole position in this challenging therapeutic space quite like we have.

Good luck at your next venture in the industry! If I know Uncle Gilead this free ride will be coming to an end soon!
Click to expand...


The Reality is Idela's 5 BLACK BOX WARNINGS and BID Dosing vs. Ibrutinib = DOG!!!
All my docs love Ibrutinib it's a losing battle... looking!!!
 






Anonymous said:
Exciting things are happening for oncology sales professionals at EMD Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany. We are significantly expanding our oncology and immuno-oncology footprint thanks in part, to the success of our R&D pipeline, and the recent partnership with Pfizer, to co-promote and co-develop immuno-oncology assets within each company.

Preparations are underway for the launch of evofosfamide, a hypoxia-targeted drug for the treatment of pancreatic adenocarcinoma. Avelumab, our fully human anti-PD-L1 therapeutic antibody, is under late stage development against several tumor types. Our development efforts will also explore the efficacy of combination therapies with existing and novel therapies.

EMD Serono is currently recruiting Key Account Managers for our Oncology division.
Click to expand...

Be careful giving out this much inside information especially to a bunch of losers.
 












Top Bottom
Back
Quote